Bipolar disorder and substance misuse: Pathological and therapeutic implications of their comorbidity and cross-sensitisation

British Journal of Psychiatry

Volumn 202, Issue 3, 2013, Pages 172-176

  Post, Robert M ^a   Kalivas, Peter ^b  

^a Bipolar Collaborative Network   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BRAIN DERIVED NEUROTROPHIC FACTOR; COCAINE;

ADDICTION; ARTICLE; BIPOLAR DISORDER; COCAINE DEPENDENCE; COMORBIDITY; CORPUS STRIATUM; DEPRESSION; DISEASE COURSE; ELECTROENCEPHALOGRAM; EPIGENETIC REPRESSION; HUMAN; MEMORY; MOOD; NONHUMAN; PATHOLOGICAL GAMBLING; RECURRENT DISEASE; STRESS; SUBSTANCE ABUSE;

ACETYLCYSTEINE; AGE OF ONSET; ANIMALS; BASAL GANGLIA; BEHAVIOR, ADDICTIVE; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM SENSITIZATION; COCAINE; COCAINE-RELATED DISORDERS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE UPTAKE INHIBITORS; EPIGENOMICS; FREE RADICAL SCAVENGERS; HUMANS; RECURRENCE; STRESS, PSYCHOLOGICAL;

EID: 84874902213     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.116855     Document Type: Article

References (27)

1. Merikangas KR, Herrell R, Swendsen J, Rossler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry 2008; 65: 47-52.
2. Lin PI, McInnis MG, Potash JB, Willour V, MacKinnon DF, DePaulo JR, et al. Clinical correlates and familial aggregation of age at onset in bipolar disorder. Am J Psychiatry 2006; 163: 240-6. (Pubitemid 44480843)
3. Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004; 55: 875-81. (Pubitemid 38526299)
4. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-75.
5. Post RM, Leverich GS. Treatment of Bipolar Illness: A Case Book for Clinicians and Patients. WW Norton, 2008.
6. Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 2010; 67: 81-4.
7. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9. (Pubitemid 36877077)
8. Covington 3rd HE, Maze I, Sun H, Bomze HM, DeMaio KD, Wu EY, et al. A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron 2011; 71: 656-70.
9. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13. (Pubitemid 41105554)
10. Kraepelin E. Manic-Depressive Insanity and Paranoia. E & S Livingstone, 1921.
11. Kessing LV, Andersen PK. Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders. Curr Psychiatry Rep 2005; 7: 413-20. (Pubitemid 43009555)
12. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009; 12: 182-9.
13. Moussawi K, Zhou W, Shen H, Reichel CM, See RE, Carr DB, et al. Reversing cocaine-induced synaptic potentiation provides enduring protection from relapse. Proc Natl Acad Sci USA 2011; 108: 385-90.
14. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-8. (Pubitemid 43228853)
15. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519-25.
16. Krishnan V, Berton O, Nestler E. The use of animal models in psychiatric research and treatment. Am J Psychiatry 2008; 165: 1109.
17. Butts KA, Weinberg J, Young AH, Phillips AG. Glucocorticoid receptors in the prefrontal cortex regulate stress-evoked dopamine efflux and aspects of executive function. Proc Natl Acad Sci USA 2011; 108: 18459-64.
18. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10: 561-72.
19. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012; 100: 801-10.
20. Mishkin M, Appenzeller T. The anatomy of memory. Sci Am 1987; 256: 80-9.
21. Xue YX, Luo YX, Wu P, Shi HS, Xue LF, Chen C, et al. A memory retrievalextinction procedure to prevent drug craving and relapse. Science 2012; 336: 241-5.
22. Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry 2009; 65: 760-9.
23. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev 2007; 8: 355-67. (Pubitemid 46652469)
24. Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 2007; 14: 268-76. (Pubitemid 46625629)
25. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12: 342-8.
26. Post RM, Leverich GS, Kupka RW, Keck Jr PE, McElroy SL, Altshuler LL, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry 2010; 71: 864-72.
27. Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE, et al. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. Int Clin Psychopharmacol 2011; 26: 96-106.